Clinical trials: Cancer, Bladder
Transitional Carcinoma of Urinary Bladder
Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary Bladder
Phase II Trial of concurrent administration of intravesical BCG \& Interferon in the treatment and prevention of recurrence of superficial transitional carcinoma of the urinary bladder.
- Trial name
- NCT00539773
- Testing
- BCG, Interferon
- Volunteers
- 10 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Muscle Invasive Bladder Carcinoma
FL- 101 Study in Non-Metastatic MIBC
A pilot window of opportunity study of FL-101 in patients with non-metastatic MIBC who are eligible for radical cystectomy (RC) but are ineligible for, or decline, cisplatin-based neoadjuvant therapy.
- Trial name
- NCT05395260
- Testing
- FL-101
- Sponsor
- Flame Biosciences
Bladder Urothelial Carcinoma
A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma
A study of the efficacy and safety of probiotics in immunotherapy of urothelial carcinoma.
- Trial name
- NCT05220124
- Testing
- Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Tianjin Medical University Second Hospital
Bladder Cancer
BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer
RATIONALE: Biological therapies, such as BCG, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00352079
- Testing
- BCG vaccine, gefitinib, quality-of-life assessment
- Where
- 6 sites in Canada
- Volunteers
- 41 people
- Sponsor
- NCIC Clinical Trials Group
Bladder Cancer, Metastatic Bladder Cancer
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer
This is a pilot study of avelumab in patients with non-metastatic, muscle invasive bladder cancer who are eligible for radical cystectomy (RC), but are ineligible for cisplatin based neoadjuvant therapy.
- Conditions
- Bladder Cancer, Metastatic Bladder Cancer, Invasive Bladder Cancer
- Trial name
- NCT03498196
- Testing
- Avelumab
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Baylor College of Medicine
Bladder (Urothelial, Transitional Cell) Cancer
Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients
When bladder cancer patients are treated to mobilize their own immune system to fight the tumor, drugs that kill the bacteria can impair the effectiveness of the treatment.
- Trial name
- NCT07119996
- Testing
- Tislelizumab, Cisplatin, Gemcitabine and Vitamin B3
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Bladder Carcinoma in Situ (CIS)
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
This is a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or…
- Trial name
- NCT05024773
- Testing
- ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
- Where
- 47 sites in United States, France and 4 more
- Volunteers
- 130 people
- Sponsor
- Fidia Farmaceutici s.p.a.
Urothelial Cancer
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Participants with metastatic or locally advanced/unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapy will be randomly assigned to receive Investigator's choice of paclitaxel…
- Trial name
- NCT02256436
- Testing
- pembrolizumab, paclitaxel, vinflunine
- Volunteers
- 542 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer, Bladder Cancer
Assessing Financial Toxicity Using the PROFFIT Questionnaire in Patients Treated With Mini-invasive Approach for Urological Malignancies.
Patients previously treated with robotic surgery for urological cancers such as prostate, bladder and kidney cancer will be enrolled, in particular patients operated in the last twelve months will be included after signing the…
- Conditions
- Prostate Cancer, Bladder Cancer, Kidney Cancer
- Trial name
- NCT06955910
- Testing
- questionnaires
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Urothelial Carcinoma
Derazantinib and Atezolizumab in Patients With Urothelial Cancer
The purpose of this study was to evaluate efficacy of derazantinib monotherapy or derazantinib-atezolizumab in combination in patients with advanced urothelial cancer harboring fibroblast growth factor receptor (FGFR) genetic…
- Trial name
- FIDES-02 (NCT04045613)
- Testing
- Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily+ atezolizumab 1200 mg
- Where
- 66 sites in United States, Australia and 12 more
- Volunteers
- 95 people
- Sponsor
- Basilea Pharmaceutica
High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
This phase I trial tests the safety and side effects of a PD-L1/IDO peptide vaccine (IO102-IO103) in combination with pembrolizumab in treating patients with non-muscle invasive bladder cancer.
- Conditions
- High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Trial name
- NCT05843448
- Testing
- PD-L1/IDO Peptide Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Davis
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other…
- Conditions
- Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma
- Trial name
- NCT03866382
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 582 sites in United States, Puerto Rico
- Volunteers
- 314 people
- Sponsor
- National Cancer Institute (NCI)
Urinary Bladder Cancer
Histopathological Findings in En-Bloc vs Conventional Transurethral Resection of Bladder Tumors.
This study is designed to determine whether en-bloc TURBT provides superior histopathological quality and clinical outcomes compared to conventional TURBT in medium-sized bladder tumors.
- Trial name
- NCT07259798
- Testing
- En bloc TURBT using a bipolar Karl-Storz resectoscope system fitted with a specialized "flat" resection loop, Bipolar piecemeal TURBT using the same bipolar Karl-Storz resectoscopic platform
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Ain Shams University
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative
- Trial name
- DUET-3 (NCT03752398)
- Testing
- XmAb®23104, Yervoy® (ipilimumab)
- Where
- 18 sites in United States
- Volunteers
- 198 people
- Sponsor
- Xencor, Inc.
Gall Bladder Cancer
Robotic-assisted Contra Open Resection for Suspected or Confirmed Gallbladder Cancer (ROBOCOP)
The Robocop trial is an international multi-centre, single blinded, randomized controlled superiority trial conducted in centres experienced in robotic-assisted liver surgery.
- Trial name
- ROBOCOP (NCT06246448)
- Testing
- Robotic-assisted radical cholecystectomy, Open radical cholecystectomy
- Where
- Sweden
- Volunteers
- 94 people
- Sponsor
- Karolinska University Hospital
Bile Duct Carcinoma, Gall Bladder Cancer
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Brief Summary: This study is for patients with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The purpose is to find out if using anti-blood vessel formation drugs after immunotherapy treatment can help…
- Conditions
- Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer, Cholangiocarcinoma
- Trial name
- SAIB (NCT07025174)
- Testing
- PD-1/CTLA-4 Dual Functional Antibody, Gemcitabine, Cisplatin, Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Solid Tumors
Cardiac Safety Assessment Study of Picoplatin in Solid Tumors
The purpose of this study is to investigate what effects, if any, picoplatin has on the heart rhythm.
- Trial name
- NCT00710697
- Testing
- Picoplatin
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Poniard Pharmaceuticals
Bladder Cancer
Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology
This study, through a clinical controlled trial, compared the one-year, three-year, and five-year overall survival rates between patients receiving a treatment plan guided by organoid drug sensitivity and those receiving…
- Trial name
- NCT07379281
- Testing
- Organoid culture
- Where
- China
- Volunteers
- 254 people
- Sponsor
- Qilu Hospital of Shandong University
Sarcopenia, Bladder Cancer
SArcopenia, Mobility, PHYsical Activity and Post-operative Risk of Bladder Carcinoma in the Elderly
Sarcopenia is associated with lower prognosis in solid tumors, but this has not been studied in bladder carcinoma requiring cystectomy.
- Trial name
- SAMPHYR (NCT03362801)
- Testing
- sarcopenia and mobility measurement
- Where
- 3 sites in France
- Volunteers
- 69 people
- Sponsor
- University Hospital, Caen
Breast Cancer, Prostate Cancer
Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
The primary objective of the study is to test a new radiotracer called 68Ga-NOTA-AE105 for PET imaging of uPAR (urokinase plasminogen activator receptor).
- Conditions
- Breast Cancer, Prostate Cancer, Urinary Bladder Cancer
- Trial name
- uPAR-PET (NCT02437539)
- Testing
- Injection of 68Ga-NOTA-AE105, Positron Emission Tomography scans
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.